Cancer - Revolution Medicines, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT06445062

Study of RAS(ON) Inhibitors in Patients with Advanced Gastrointestinal Solid Tumors, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), cholangiocarcinoma, appendiceal cancer, gastric cancer, and other GI cancers. 

Drug

RMC-6236

Condition

The subprotocols under this master protocol will enroll patients with gastrointestinal solid tumors which may include pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), cholangiocarcinoma, appendiceal cancer, gastric cancer, and other GI ca